Sensus Healthcare Reports 59% Q1 Revenue Decline, Worsening Profitability Amidst Strategic Shift
SRTS sits 27% above its 52-week low of $3.03.
Summary
Sensus Healthcare reported a 59% year-over-year revenue decline to $3.4 million in Q1 2026, alongside worsening profitability and continued cash burn, despite strategic initiatives around new CPT codes.
Key Events · Earnings and Guidance · SRTS
-
Significant Revenue Decline
Q1 2026 revenue fell 59% year-over-year to $3.4 million, primarily due to the absence of sales to its historically largest customer. This follows a 34% revenue decrease in 2025.
-
Worsening Profitability
Gross margin decreased to 29.2% from 52.2% in the prior-year period, and Adjusted EBITDA worsened to negative $4.2 million compared to negative $2.5 million in Q1 2025.
-
Continued Cash Burn
Cash and cash equivalents decreased by $3.8 million during the quarter, ending at $18.3 million as of March 31, 2026.
-
Strategic Initiatives Highlighted
The company emphasized the positive impact of new dedicated CPT codes for SRT, effective January 1, 2026, which are driving increased customer inquiry and pipeline activity, alongside new financial services and product launches.
Analysis · SRTS · Industrial Applications And Services
Sensus Healthcare's Q1 2026 results reveal a significant deterioration in financial performance, with revenue plummeting 59% year-over-year. This substantial decline, primarily attributed to the loss of its largest customer, exacerbates the negative trends observed in 2025, which included a 34% revenue decrease and a credit facility covenant default. The worsening gross margin and Adjusted EBITDA, coupled with continued cash burn, highlight immediate operational challenges. While the company points to new CPT codes for Superficial Radiotherapy (SRT) as a future growth driver, the current financial health remains a critical concern for investors.
At the time of this filing, SRTS was trading at $3.86 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $67.7M. The 52-week trading range was $3.03 to $5.92. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.